Get the Daily Brief
Latest Biotech News
AbbVie Inks $700 Million Deal for Trispecific Antibody in Multiple Myeloma
AbbVie has acquired global rights to a trispecific antibody, ISB-2001, from IGI Therapeutics for $700 million upfront, with potential milestone and royalty payments reaching nearly $2 billion. The...
Launch of Center for Pediatric CRISPR Therapies Funded by CZI and IGI
The Chan Zuckerberg Initiative and the Innovative Genomics Institute have jointly funded a new Center for Pediatric CRISPR Cures with a $20 million grant. The center aims to advance personalized...
New AI Models Advance Prediction of Cell and Protein Dynamics
Innovative AI platforms are reshaping biological modeling, improving insights into cell behavior and protein dynamics essential for drug discovery. The GREmLN model developed by Columbia...
Soleno Therapeutics Reports Strong Early Sales for Prader-Willi Syndrome Drug
Soleno Therapeutics’ Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, has exceeded expectations in its initial full-quarter sales, with net revenues projected...
Nuclidium and Actithera Secure Significant Funding to Fuel Radiopharmaceutical Development
European radiopharmaceutical companies Nuclidium AG and Actithera A/S have attracted substantial venture capital to progress clinical development efforts. Nuclidium closed a CHF79 million ($99...
Jazz Pharmaceuticals Names Renee Galá as New CEO Amid Leadership Transition
Jazz Pharmaceuticals has appointed Renee Galá, its current president and chief operating officer, as the next CEO effective August 11, 2025. Galá succeeds co-founder Bruce Cozadd, who plans to...
Merck Boosts Respiratory Portfolio with $10B Verona Pharma Buyout
Merck & Co. announced the acquisition of Verona Pharma for $10 billion, securing Ohtuvayre, a novel maintenance treatment for chronic obstructive pulmonary disease (COPD). Ohtuvayre combines...
FDA Publishes First Batch of Drug Rejection Letters in Transparency Move
In an unprecedented policy shift, the FDA made public an initial set of over 200 complete response letters (CRLs) issued to drug sponsors between 2020 and 2024. These letters detail the agency’s...
FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy
The FDA issued a Complete Response Letter rejecting Capricor Therapeutics' application for approval of deramiocel, an allogeneic cell therapy for cardiomyopathy in Duchenne muscular dystrophy...
Pfizer and Astellas Show Combo Therapy Boost in Early Prostate Cancer Survival
Pfizer and Astellas released positive Phase 3 data from their Embark trial demonstrating that combining Xtandi (enzalutamide) with leuprolide significantly improves overall survival for men with...
AI Model GREmLN Captures Gene Regulatory Networks to Enhance Disease Understanding
Researchers at Columbia University and the Chan Zuckerberg Initiative unveiled GREmLN, a novel graph-based artificial intelligence model designed to capture complex gene regulatory networks from...
New Radiopharma Startups Secure Major Funding Rounds to Advance Diagnostics and Therapeutics
Radiopharmaceutical biotech companies Nuclidium and Actithera have raised sizable capital rounds to develop novel diagnostic and therapeutic platforms. Swiss-German Nuclidium secured $99 million...
Jazz Names Renée Galá Successor as CEO; Executive Moves Stir Biotech Sector
Jazz Pharmaceuticals announced the promotion of current President and Chief Operating Officer Renée Galá as its incoming CEO, succeeding co-founder Bruce Cozadd in August. This leadership...
Intranasal Monoclonal Antibody Reduces Pollen Allergy and Asthma Symptoms in Mouse Model
Researchers at Kazakh National Agrarian Research University engineered an intranasal monoclonal antibody targeting mugwort pollen allergen that effectively prevented hay fever and asthma symptoms...
Actithera’s FAP-Targeted Radiopharmaceutical Raises $75 Million in Series A
Danish biotech Actithera A/S has closed a $75.5 million Series A financing round to fund early clinical development of its lead radiopharmaceutical candidate targeting fibroblast activation...
Merck’s $10 Billion Acquisition: Reinforcing Respiratory Portfolio with Verona Pharma
Merck & Co. has entered a definitive $10 billion agreement to acquire London-based Verona Pharma, bolstering its cardiopulmonary drug portfolio with Ohtuvayre (ensifentrine), a first-in-class...
AbbVie’s $700 Million Investment: Securing Trispecific Antibody for Multiple Myeloma
AbbVie has inked a landmark deal worth $700 million upfront with IGI Therapeutics for exclusive rights to ISB-2001, a trispecific antibody targeting BCMA, CD38, and CD3, showing promise in...
FDA’s Novel Transparency Effort: Publishing Drug Rejection Letters for Approved Products
The U.S. Food and Drug Administration (FDA) has initiated a historic transparency measure by releasing over 200 complete response letters (CRLs) issued to drug and biologic sponsors whose products...
Pfizer and Astellas Expand Xtandi Label With New Survival Benefits in Early Prostate Cancer
Pfizer and Astellas have announced encouraging phase 3 data from the EMBARK trial demonstrating that Xtandi (enzalutamide), in combination with leuprolide, significantly improves overall survival...
Center for Pediatric CRISPR Therapies Funded to Advance Ultra-Rare Disease Gene Editing
The Chan Zuckerberg Initiative (CZI) and Innovative Genomics Institute (IGI) have jointly funded the creation of the Center for Pediatric CRISPR Cures, aiming to develop personalized CRISPR-based...